Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViroGates AS's gross profit for the
three
months ended in Mar. 2026 was €0.13 Mil. ViroGates AS's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €0.95 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. ViroGates AS's gross profit for the
three
months ended in Mar. 2026 was €0.13 Mil. ViroGates AS's Revenue for the
three
months ended in Mar. 2026 was €0.17 Mil. Therefore, ViroGates AS's Gross Margin % for the quarter that ended in Mar. 2026 was 75.29%.
ViroGates AS had a gross margin of 75.29% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 10 years, the highestGross Margin % of ViroGates AS was 90.59%. The lowest was 67.33%. And the median was 83.18%.
Warning Sign:
ViroGates AS gross margin has been in long-term decline. The average rate of decline per year is -1.9%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ViroGates AS had a gross margin of 75.29% for the quarter that ended in Mar. 2026 => Durable competitive advantage
ViroGates AS Gross Profit Related Terms
ViroGates AS Gross Profit Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ViroGates AS's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Gross Profit distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.95 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ViroGates AS (FRA:EP2) has a Gross Profit of €0.95 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on ViroGates AS and its competitors.
Is ViroGates AS's Gross Profit too high?
ViroGates AS's current Gross Profit is €0.95 Mil. Overall, ViroGates AS has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Gross Profit compare to ABT and SYK?
ViroGates AS's Gross Profit of €0.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on ViroGates AS and its competitors. ViroGates AS's current Gross Profit is €0.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (FRA:EP2) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.87, compared to a current price of €1.45 — trading 66.7% above its estimated fair value. The current Gross Profit is €0.95 Mil. ViroGates AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current Gross Profit is €0.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (FRA:EP2) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of €1.45 is trading 66.7% above its estimated GF Value™ of €0.87.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for FRA:EP2:
Gross Profit: €0.95 Mil
GF Value™: €0.87 vs. price of €1.45 (66.7% above fair value)
No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
24GF Score
Get the complete analysis for FRA:EP2
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EP2 has been successfully added to your 
